Short Interest in SOPHiA GENETICS SA (NASDAQ:SOPH) Declines By 26.5%

SOPHiA GENETICS SA (NASDAQ:SOPH) saw a large drop in short interest in the month of December. As of December 15th, there was short interest totaling 32,434 shares, a drop of 26.5% from the November 30th total of 44,138 shares. Approximately 0.1% of the shares of the company are short sold. Based on an average daily trading volume, of 99,157 shares, the short-interest ratio is currently 0.3 days. Based on an average daily trading volume, of 99,157 shares, the short-interest ratio is currently 0.3 days. Approximately 0.1% of the shares of the company are short sold.

Analysts Set New Price Targets

SOPH has been the topic of several recent research reports. Weiss Ratings restated a “sell (d-)” rating on shares of SOPHiA GENETICS in a research report on Wednesday, October 8th. BTIG Research raised their target price on SOPHiA GENETICS from $6.00 to $7.00 and gave the stock a “buy” rating in a research note on Monday, November 10th. Finally, Wall Street Zen raised SOPHiA GENETICS to a “hold” rating in a report on Saturday, November 1st. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $7.00.

SOPHiA GENETICS Trading Up 2.8%

Shares of NASDAQ SOPH traded up $0.13 during midday trading on Tuesday, reaching $4.78. The company had a trading volume of 39,418 shares, compared to its average volume of 81,982. The company has a quick ratio of 2.62, a current ratio of 2.80 and a debt-to-equity ratio of 0.78. SOPHiA GENETICS has a one year low of $2.58 and a one year high of $5.30. The firm’s fifty day moving average price is $4.60 and its 200-day moving average price is $3.90. The stock has a market cap of $323.03 million, a PE ratio of -10.39 and a beta of 1.10.

SOPHiA GENETICS (NASDAQ:SOPH) last issued its quarterly earnings data on Tuesday, November 4th. The company reported ($0.30) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.10). The business had revenue of $19.46 million during the quarter, compared to the consensus estimate of $18.13 million. SOPHiA GENETICS had a negative return on equity of 37.75% and a negative net margin of 41.13%. On average, equities research analysts anticipate that SOPHiA GENETICS will post -0.96 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in SOPH. Savvy Advisors Inc. purchased a new stake in shares of SOPHiA GENETICS in the third quarter worth $48,000. Squarepoint Ops LLC purchased a new position in SOPHiA GENETICS in the 3rd quarter worth approximately $49,000. GSA Capital Partners LLP bought a new position in SOPHiA GENETICS in the 3rd quarter worth approximately $59,000. Susquehanna International Group LLP purchased a new stake in SOPHiA GENETICS during the 3rd quarter valued at approximately $88,000. Finally, Silverberg Bernstein Capital Management LLC lifted its holdings in shares of SOPHiA GENETICS by 31.8% in the second quarter. Silverberg Bernstein Capital Management LLC now owns 45,715 shares of the company’s stock worth $142,000 after buying an additional 11,040 shares in the last quarter. Institutional investors own 31.59% of the company’s stock.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.